Executive Insights: CRC Screening Outlook w/ Geneoscopy | Sept. 13, 2:30 PM ET | The RNA Opportunity

Overview

We’re excited to have Geneoscopy Co-Founders Erica Barnell (Chief Scientific Officer) and Andrew Barnell (CEO) join us for an interview focused on colorectal cancer (CRC) screening trends. We became interested in Geneoscopy's story following the late-May announcement of the peer-reviewed article, “Multitarget Stool RNA Test for Noninvasive Detection of Colorectal Neoplasias in a Multicenter, Prospective, and Retrospective Cohort,” which presented the results of the company's multifactor RNA-FIT test in Clinical and Translational Gastroenterology. Our tracking of the genetic testing space and Position Monitor Companies, including Natera, NeoGenomics, Invitae, Guardant, and Exact Sciences, involves our claims and other macro data series that inform the models and return to in-person care thesis, but it also seems like competition has intensified recently in/around routine screening, especially for CRC given revised screening guidelines (45+), treatment selection/CDx, and of course MRD. Then there's the whole pan-cancer/value of early detection debate - i.e., whether Grail and/or Thrive can ultimately deliver.

Hedgeye Health Care Sector Head Tom Tobin will lead the discussion, which will highlight Geneoscopy's work to date, how the standard of care and pathways are evolving, why non-invasive tests have been suboptimal for preventing CRC, as well as several key points related to stool vs. blood and RNA vs. DNA tests. Please send questions for Erica, Andrew, and Tom to .

Discussion Topics:

1. The issue(s) with the current standard of care and colonoscopy - the importance of adenoma detection
2. Geneoscopy's progress with its RNA-FIT assay, highlights from published data, next steps
3. The impact of the pandemic on trials/studies, decentralized trials
4. How RNA-FIT can change the playing field - implications for primary care physicians, GIs, and D2C
5. Liquid biopsy opportunities and tumor naïve vs. tumor informed tests
6. Pan-cancer screening - timeline and speed bumps or mountains to go over?

About the Speakers

Erica Barnell, Ph.D., is Co-Founder & Chief Science Officer of Geneoscopy. Dr. Barnell graduated from Cornell University with a dual degree in Biological Sciences and Applied Economics & Management and is an MD/Ph.D. candidate at the Washington University School of Medicine. In 2019, she completed her Ph.D. at the McDonnell Genome Institute. Her thesis work surrounded the development of bioinformatic tools to alleviate the analysis bottleneck within precision oncology. Dr. Barnell has published 19 peer-reviewed manuscripts, 11 abstracts with 4 platform presentations, and two book chapters within the oncology space. She conducted the original research to validate Geneoscopy’s stool extraction method and managed all feasibility studies for Geneoscopy’s colorectal cancer (CRC) screening test and was responsible for existing engagement with the FDA, which includes holding three presubmission meetings and obtaining Breakthrough Device Designation for the lead CRC screening test. Dr. Barnell is the lead inventor on all patents pertaining to Geneoscopy’s technology and is currently the site investigator on two IRB-approved protocols.

Andrew Barnell, MBA, is Co-Founder & CEO of Geneoscopy. Andrew graduated from Cornell University with a Bachelor’s degree in Applied Economics & Management and a specialization in Finance. He received an MBA in Health Care Management and Entrepreneurial Management from The Wharton School. Andrew began his career as a financial analyst in J.P. Morgan’s healthcare investment banking group, working primarily on M&A and capital markets transactions. He also worked as an associate at Lindsay Goldberg, a middle-market private equity firm focused on partnering with family-owned businesses.

We hope you can join us! 

Thomas Tobin
Managing Director


Twitter
LinkedIn

Justin Venneri
Director, Primary Research


Twitter
LinkedIn

William McMahon
Analyst


Twitter
LinkedIn